Literature DB >> 33994726

Etiologic Role of Kinases in the Progression of Human Cancers and Its Targeting Strategies.

Sanjoy Das1, Bireswar Bhattacharya2, Biplajit Das1, Bibek Sinha1, Taison Jamatia1, Kishan Paul1.   

Abstract

Cancer is one of the dominant causes of death worldwide while lifelong prognosis is still inauspicious. The maturation of the cancer is seen as a process of transformation of a healthy cell into a tumor-sensitive cell, which is held entirely at the cellular, molecular, and genetic levels of the organism. Tyrosine kinases can play a major, etiologic role in the inception of malignancy and devote to the uncontrolled proliferation of cancerous cells and the progression of a tumor as well as the development of metastatic disease. Angiogenesis and oncogene activation are the major event in cell proliferation. The growth of a tumor and metastasis are fully depending on angiogenesis and lymphangiogenesis triggered by chemical signals from tumor cells in a phase of rapid growth. Tyrosine kinase inhibitors are compounds that inhibit tyrosine kinases and effective in targeting angiogenesis and blocking the signaling pathways of oncogenes. Small molecule tyrosine kinase inhibitors like afatinib, erlotinib, crizotinib, gefitinib, and cetuximab are shown to a selective cut off tactic toward the constitutive activation of an oncogene in tumor cells, and thus contemplated as promising therapeutic approaches for the diagnosis of cancer and malignancies. © Indian Association of Surgical Oncology 2019.

Entities:  

Keywords:  Angiogenesis; Antibodies; Cancer; Kinases; Oncogene; Tyrosine kinase inhibitors

Year:  2019        PMID: 33994726      PMCID: PMC8119588          DOI: 10.1007/s13193-019-00972-z

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  158 in total

Review 1.  Cell adhesion molecules: selectins and integrins.

Authors:  R González-Amaro; F Sánchez-Madrid
Journal:  Crit Rev Immunol       Date:  1999       Impact factor: 2.214

2.  Erlotinib and gefitinib, epidermal growth factor receptor kinase inhibitors, may treat non-cancer-related tumor necrosis factor-α mediated inflammatory diseases.

Authors:  Marvin B Brooks
Journal:  Oncologist       Date:  2013

Review 3.  Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics.

Authors:  Raoul Tibes; Jonathan Trent; Razelle Kurzrock
Journal:  Annu Rev Pharmacol Toxicol       Date:  2005       Impact factor: 13.820

Review 4.  Protein tyrosine kinase structure and function.

Authors:  S R Hubbard; J H Till
Journal:  Annu Rev Biochem       Date:  2000       Impact factor: 23.643

Review 5.  Cell adhesion molecules: role and clinical significance in cancer.

Authors:  Nektaria Makrilia; Anastasios Kollias; Leonidas Manolopoulos; Kostas Syrigos
Journal:  Cancer Invest       Date:  2009-12       Impact factor: 2.176

Review 6.  The role of fibroblast growth factors in tumor growth.

Authors:  M Korc; R E Friesel
Journal:  Curr Cancer Drug Targets       Date:  2009-08-01       Impact factor: 3.428

Review 7.  Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy.

Authors:  Federica Biello; Giovanni Burrafato; Erika Rijavec; Carlo Genova; Giulia Barletta; Anna Truini; Simona Coco; Maria Giovanna Dal Bello; Angela Alama; Francesco Boccardo; Francesco Grossi
Journal:  Anticancer Agents Med Chem       Date:  2016       Impact factor: 2.505

Review 8.  Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives.

Authors:  Michael B Atkins; James Larkin
Journal:  J Natl Cancer Inst       Date:  2016-02-02       Impact factor: 13.506

9.  An autocrine/paracrine circuit of growth differentiation factor (GDF) 15 has a role for maintenance of breast cancer stem-like cells.

Authors:  Asako Sasahara; Kana Tominaga; Tatsunori Nishimura; Masao Yano; Etsuko Kiyokawa; Miki Noguchi; Masakuni Noguchi; Hajime Kanauchi; Toshihisa Ogawa; Hiroshi Minato; Keiichiro Tada; Yasuyuki Seto; Arinobu Tojo; Noriko Gotoh
Journal:  Oncotarget       Date:  2017-04-11

10.  Activation of signaling receptors: do ligands bind to receptor monomer, dimer, or both?

Authors:  Xiaodong Pang; Huan-Xiang Zhou
Journal:  BMC Biophys       Date:  2013-06-03       Impact factor: 4.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.